September 25, 2018
Otsuka Pharmaceutical Co., Ltd.
Busulfex Injection 60mg Approved in Japan for Once-Daily Administration in Adults
Busulfex is used around the world as a pretreatment prior to hematopoietic stem cell transplantation in patients with hematologic cancers
The approval in Japan reflects the once-daily usage pattern for Busulfex in adults in other countries
The addition of a once-daily dosage regimen is expected to reduce the burdens and risks for patients and medical staff
Otsuka Pharmaceutical Co., Ltd. today announces it has received regulatory approval for a once-daily form of Busulfex® Injection 60 mg (generic name is busulfan). Busulfex is a conditioning regimen administered via intravenous drip to patients prior to undergoing hematopoietic stem cell transplantation.
Information in this news release was current as of the original release date.